A feedback assembly of a medicament delivery device
The feedback assembly in medicament delivery devices addresses the need for clear feedback by using geometrically distinct parts to provide audible, tactile, and visual cues, enhancing user experience and ensuring proper operation.
Patent Information
- Application Number
- PCT/EP2026/060171
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-04-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing medicament delivery devices lack effective feedback mechanisms to clearly indicate the status of the device and operation to end users, particularly for self-administration by patients without formal medical training.
A feedback assembly comprising a stationary part and a movable part with geometrically distinct feedback members, providing multiple types of feedback such as audible, tactile, and visual cues through interactions between the parts, enhancing user awareness during the medicament delivery process.
The feedback assembly provides clear and differentiated feedback to users, improving the usability and confidence of self-administration by patients, ensuring proper operation and medicament delivery.
Smart Images

Figure EP2026060171_12112026_PF_FP_ABST
Abstract
Description
[0001] A FEEDBACK ASSEMBLY OF A MEDICAMENT DELIVERY DEVICE TECHNICAL FIELD
[0002] The present invention relates to a feedback assembly of a medicament delivery device and more particularly to the feedback assembly comprising a first feedback member and a second feedback member being geometrically different from the first feedback member.
[0003] BACKGROUND
[0004] Medicament delivery devices such as auto-injectors, inhalers, on-body devices are generally known for the self-administration of a medicament by patients without formal medical training occurs. For example, those patients suffering from diabetes or those people are taking the artificial fertilization procedure may require repeated injections of insulin or hormone. Other patients may require regular injections of other types of medicaments, such as a growth hormone.
[0005] Medicament delivery devices may be delivery to end users with prefilled medicament containers. A medicament container usually constructed by a glass or plastic barrel with a stopper sealing on its rear end and a delivery member arranged on its front end; or a pierceable membrane arranged on its front end. Most of time, the medicament container will be filed with specific medicament first, then be assembled into a medicament delivery device. The medicament delivery device usually comprises a plunger rod configured to push on the stopper of the medicament container to deliver the contained medicament to an end user under force of a drive element, a spring, or a pressurized gas It is desirable to provide feedback that is able to clearly indicate end users about the situation of the medicament delivery device and / or the medicament delivery operation.
[0006] In most instances this solution works very well. However, there is also a demand to have a further improvement on the disclosed medicament delivery device.
[0007] SUMMARY
[0008] The invention is defined by the appended claims, to which reference should now be made.
[0009] In the present disclosure, when the term “distal direction” is used, this refers to the direction pointing away from the dose delivery site during use of the medicament delivery device. When the term “distal part / end” is used, this refers to the part / end of the delivery device, or the parts / ends of the members thereof, which under use of the medicament delivery device is / are located furthest away from the dose delivery site. Correspondingly, when the term “proximal direction” is used, this refers to the direction pointing towards the dose delivery siteduring use of the medicament delivery device. When the term “proximal part / end” is used, this refers to the part / end of the delivery device, or the parts / ends of the members thereof, which under use of the medicament delivery device is / are located closest to the dose delivery site.
[0010] Further, the term “longitudinal”, “longitudinally”, “axially” or “axial” refer to a direction extending from the proximal end to the distal end, typically along the device or components thereof in the direction of the longest extension of the device and / or component.
[0011] Similarly, the terms “transverse”, “transversal” and “transversally” refer to a direction generally perpendicular to the direction of the longitudinal axis.
[0012] Further, the terms “circumference”, “circumferential”, or “circumferentially” refer to a circumference or a circumferential direction relative to an axis, typically a central axis extending in the direction of the longest extension of the device and / or component. Similarly, “radial” or “radially” refer to a direction extending radially relative to the axis, and “rotation”, “rotational” and “rotationally” refer to rotation relative to the axis.
[0013] There is hence provided a feedback assembly of a medicament delivery device, the feedback assembly comprising: a stationary part and a movable part being movable relative to the stationary part; wherein the stationary part and the movable part are configured to be accommodated within a housing of the medicament delivery device; wherein the movable part is configured to be operably attached to a plunger rod of the medicament delivery device, or a driver of the medicament delivery device; wherein the movable part is configured to be in contact and be moved relative to the stationary part; wherein the stationary part comprises a first feedback member and a second feedback member being geometrically different from the first feedback member; and wherein the movable part comprises a counter feedback member configured to interact with the first feedback member and the second feedback member when the movable part is moved relative to the stationary part such that a first feedback is generated during the counter feedback member interacts with the first feedback member and a second feedback is generated during the counter feedback member interacts with the second feedback member thereby at least two different feedback are provided.
[0014] According to one embodiment, the magnitude of the first feedback is different from the magnitude of the second feedback.
[0015] According to one embodiment, the frequency of the first feedback is different from the frequency of the second feedback.
[0016] According to one embodiment, the first feedback is an audible and / or tactile feedback.According to one embodiment, the second feedback is an audible and / or tactile feedback.
[0017] According to one embodiment, the counter feedback member is a flexible arm.
[0018] According to one embodiment, the first feedback member comprises a first protrusion.
[0019] According to one embodiment, the second feedback member comprises a second protrusion.
[0020] According to one embodiment, the first protrusion and the second protrusion are dimensionally different from one another.
[0021] According to one embodiment, the first feedback member comprises a first set of structural patterns.
[0022] According to one embodiment, the second feedback member comprises a second set of structural patterns.
[0023] According to one embodiment, the structural patterns and the second structural patterns are geometrically different from one another.
[0024] Another aspect of the disclosure provides a medicament delivery device comprises the feedback assembly according to any one of the preceding embodiments.
[0025] According to one embodiment, the medicament delivery device comprises a housing extending along a longitudinal axis from a proximal end and a distal end.
[0026] According to one embodiment, the housing is configured to accommodate a medicament container containing medicament.
[0027] According to one embodiment, the medicament delivery device comprises a plunger rod operably connected to a power source such that the plunger rod is configured to be moved relative to the housing by the power source to expel the contained medicament.
[0028] According to one embodiment, the movable part of the feedback assembly is operably attached to the plunger rod.
[0029] According to one embodiment, the medicament delivery device comprises a drive connected to the plunger rod and the power source such that the plunger rod is configured to be moved relative to the housing by the power source to expel the contained medicament via the drive.
[0030] According to one embodiment, the movable part of the feedback assembly is operably attached to the driver.According to one embodiment, the movable part of the feedback assembly is operably attached to the plunger rod.
[0031] According to one embodiment, the movable part is configured to be rotated relative to the housing around the longitudinal axis.
[0032] According to one embodiment, the movable part is operably connected to a third feedback member such that third feedback is provided when the movable part is moved relative to the stationary part.
[0033] According to one embodiment, the third feedback is a different type of feedback than the first feedback and the second feedback.
[0034] According to one embodiment, the housing of the medicament delivery device comprises a transparent section.
[0035] According to one embodiment, the third feedback member comprises a rotating piece such that the rotating piece is configured to be rotated by the movable part when the movable part is moved relative to the stationary part.
[0036] According to one embodiment, a visual indication is provided via the transparent section of the housing when the rotating piece is rotated.
[0037] According to one embodiment, the transparent section is positioned closer to the distal end of the housing than the proximal end of the housing.
[0038] According to one embodiment, the medicament delivery device comprises a medicament container.
[0039] According to one embodiment, the medicament container is configured to accommodate the medicament between 2.25ml to 5.5ml.
[0040] According to one embodiment, the medicament container is a 3ml cartridge / syringe or a 5ml cartridge / syringe.
[0041] According to one embodiment, the medicament container is made of glass or plastic.
[0042] According to one embodiment, the medicament delivery device can be an injection device, e.g., an autoinjector.
[0043] Other aspects, features, and advantages will be apparent from the summary above, as well as from the description that follows, including the figures and the claims.Generally, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to "a / an / the element, apparatus, component, means, etc. are to be interpreted openly as referring to at least one instance of the element, apparatus, component, means, etc.”, unless explicitly stated otherwise.
[0044] BRIEF DESCRIPTION OF THE DRAWINGS
[0045] The specific embodiments of the inventive concept will now be described, by way of example, with reference to the accompanying drawings, in which:
[0046] Fig. 1 schematically displays a medicament delivery device comprising a feedback assembly of the disclosure;
[0047] Fig. 2 schematically displays a perspective view of a stationary part of the feedback assembly of Fig. 1 ;
[0048] Fig. 3 schematically displays a perspective view of a movable part of the feedback assembly of Fig. 1;
[0049] Fig. 4 schematically displays a perspective view of a movable part of the feedback assembly of Fig. 1 in another example;
[0050] Figs 5-8 schematically display perspective views of stationary parts in different examples, respectively;
[0051] Figs 9-10 schematically display perspective views of movable parts in different examples, respectively;
[0052] Fig. 11 schematically displays a perspective view of the feedback assembly of Fig. 1 in another example;
[0053] Figs 12-13 schematically display perspective views of a medicament delivery device comprising the feedback assembly of Fig. 1 ; and
[0054] Figs 14-16 schematically display perspective views of stationary part and the movable part in different examples, respectively.DETAILED DESCRIPTION
[0055] The present application is directed to a feedback assembly for a medicament delivery device and will now be described more fully hereinafter with reference to the accompanying drawings, in which exemplifying embodiments are shown. The feedback assembly may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided by way of example so that this disclosure will be thorough and complete, and will fully convey the scope of the inventive concept to those skilled in the art. Like numbers refer to like elements throughout the description.
[0056] Figs 1-16 illustrates a feedback assembly of a medicament delivery device of the disclosure. The feedback assembly comprises a stationary part 1 ; T and a movable part 2; 2’ being movable relative to the stationary part. In one example, the stationary part 1 is configured to be operably attached to a housing 40 of the medicament delivery device.
[0057] The stationary part 1 ;1 ’ comprises a body 10; 10’ extending along a longitudinal axis L from a proximal end to a distal end. The movable part 2; 2’ is configured to be operably attached to a plunger rod 9; 9’ of the medicament delivery device, as shown in Fig. 16, or a driver 43 of the medicament delivery device. Thus, the movement of the movable part 2; 2’ can reflect a progress of the medicament delivery operation. In one example as shown in Fig. 13, the movable part 2 is operably attached to the driver 43 of the medicament delivery device. Alternatively, or additionally, the movable part 2; 2’ is an integral part of the driver or the plunger rod (as shown in Fig. 14). For example, the stationary part 1 ’ is configured to be attached to the driver 43 of the medicament delivery device, e.g., as an integral part of the driver 43 (as shown in Figs 14-15), in this example, the movable part 2’ is configured to be driven by the driver 43 of the medicament delivery device. In one example, the driver 43 is rotationally locked to the movable part 2’ (in this example, the movable part 2’ is an integral part of the plunger rod of the medicament delivery device), but axially movable relative the movable part 2’. This example is suitable for the medicament delivery device comprises a power source delivering a torque to rotate the driver 43.
[0058] The driver 43 of the medicament delivery device is configured to be attached to the power source 8 and is attached to the plunger rod 9; 9’ of the medicament delivery device. As a result, the plunger rod 9; 9’ can be moved by the power source 8 via the driver 43. In one example, the power source 8 is a spring, e.g., a compression spring or a torsion spring. The movable part 2; 2’ is configured to be in contact and be moved relative to the stationary part 1 ; T. The stationary part 1 ; T comprises a first feedback member 11a; 11a’; 11 a”; 11 a’”; 11 a”” and a second feedback member 11b; 11b’; 11b”; 11 b’”; 11 b”” being geometrically different from the first feedback member 11a. In examples shown in Fig. 2, Figs 5-6, thestationary part 1 comprises the first feedback member 11a; 11a’; 11 a”; 11 a’”; 11 a””, the second feedback member 11b; 11b’; 11 b”; 11 b’”; 11 b””, a third feedback member 11c, 11c’, 11c”, 11c’” and a fourth feedback member 11 d , 11 d’, 11 d”, 11 d’”. In one example, the first feedback member 11 a and the third feedback member are geometrically identical, as shown in Fig. 5. In another example, the first feedback member 11 a”; 11 a’”; 11 a”” and the second feedback member 11 b”; 11 b’”; 11 b””, comprises different structural patterns, respectively, as shown in Figs 7-8 and Fig. 14. The movable part 2; 2’ comprises a counter feedback member 21 a, 21 b; 21 a’; 21 a”, 21 b”, 21c”; 21 a’”, 21 b’” configured to interact with the first feedback member 11a; 11a’; 11 a”; 11 a’”; 11 a”” and the second feedback member 11 b; 11b’; 11 b”; 11 b’”; 11 b”” when the movable part 2 is moved relative to the stationary part 1 ; I ’ such that a first feedback is generated during the counter feedback member 21 a, 21 b; 21 a’; 21a”, 21 b”, 21 c”; 21 a’”, 21 b’” interacts with the first feedback member 11a; 11a’; 11 a”; I I a’”; 11 a”” and a second feedback is generated during the counter feedback member 21a, 21 b; 21 a’; 21 a”, 21 b”, 21c”; 21 a’”, 21 b’” interacts with the second feedback member 11 b; 11b’; 11 b”; 11 b’”; 11 b”” thereby at least two different feedback are provided, as shown in Figs 9-10.
[0059] In one example, the first feedback member comprises a first protrusion and the second feedback member comprises a second protrusion. The first protrusion and the second protrusion are dimensionally different from one another. In another example, the first feedback member comprises a first set of recesses / cutouts 11a”” and the second feedback member comprises a second set of recesses / cut-outs 11b””, as shown in Fig. 14. In this example, the recesses / cutouts 11a”” of the first feedback member are spaced from one another with a first distance; and the recesses / cutouts 11b”” of the second feedback member are spaced from one another with a second distance different from the first distance.
[0060] In one example, the magnitude of the first feedback is different from the magnitude of the second feedback. For example, the first feedback member 11 a comprises a protruding edge 112 positioned between a first ledge 110 and a second ledge 111. The distance between the protruding edge and the second ledge 111 defines a first length. The second feedback member 11 b comprises the same structure as the first feedback member 11 a, namely that a protruding edge positioned between a first ledge and a second ledge. The distance between the protruding edge and the second ledge of the second feedback member defines a second length. In the example as shown in Fig. 5, the second length is greater than the first length. As a result, when the counter feedback member 21 a, 21 b; 21 a’ moves past the protruding edge of the second feedback member 11b, a louder click sounds can be generated compared to the counter feedback member 21 a, 21 b; 21 a’ moves past the protruding edge of the first feedback member 11a. Alternatively, the frequency of the first feedback isdifferent from the frequency of the second feedback. For example, the first feedback member comprises a first set of structural patterns; and the second feedback member comprises a second set of structural patterns. In this example, the structural patterns and the second structural patterns are geometrically different from one another. For example, as shown in Figs 7,8 or 14-15, the first feedback member 11a”; 11 a”’comprises ratchet teeth 11a”; 11a’” or first set of cutouts 11a””. In this example, the second feedback member comprises ratchet teeth 11 b”; 11 b’” or first set of cutouts 11 b”” in different patterns with the ratchet teeth of the first feedback member. As a result, the frequency of the first feedback is different from the frequency of the second feedback.
[0061] In one example, the first feedback is an audible and / or tactile feedback, and the second feedback is an audible and / or tactile feedback.
[0062] In one example, the counter feedback member 21 a, 21 b; 21 a’; 21 a”, 21 b”, 21 c”; 21 a’”, 21 b’” is a flexible arm. In one example, the counter feedback member is a pair of flexible arms 21 a, 21 b; 21 a’”, 21 b’”. In another example, the counter feedback member comprises three flexible arms 21a”, 21b”, 21c”, as shown in Fig. 13.
[0063] In one example where the stationary part 1 is attached to the housing 40 of the medicament delivery device and the movable part 2 is operably connected to the driver 43 of the medicament delivery device, as shown in Figs 1-4, the movable part 2 is configured to be rotated by the driver 43 during the medicament delivery operation. Thus, the counter feedback member 21 a, 21 b; 21 a’; 21 a”, 21 b”, 21c”, being at least one flexible arm, snaps over the first feedback member and the second feedback member and thereby generates two different feedback are provided. In another example, the movable part 2 is configured to be rotated by the plunger rod 9, as shown in Fig. 16. In this example, the plunger rod 9 comprises a thread part 90 and a groove part 91. The movable part 2 comprises a body enclosing the plunger rod 9 and a ledge 23 engaged with the groove part 91 of the plunger rod 9. As a result, the plunger rod 9 is connected to the driver 43 and being rotated by the driver 43. The thread part 90 of the plunger rod 9 allows the plunger rod 9 to be moved forward by the rotation when the thread part 90 interacts with a counter thread insert operably connected to the housing 40 of the medicament delivery device. The movable part 2 is rotated by the plunger rod 9 due to the engagement between the ledge 23 and the groove part 91. Thus, the movable part 2 is configured to be rotated by the plunger rod 9 during the medicament delivery operation. Thus, the counter feedback member 21 a, 21 b; 21 a’; 21a”, 21 b”, 21 c”, being at least one flexible arm, snaps over the first feedback member and the second feedback member and thereby generates two different feedback are provided. In another example, the movable part 2’ is an integral part of the plunger rod 9’, as shown in Fig. 14. In this example, the plunger rod 9’ comprises a flexible arm at the distal end 21a’”, 21b’” as the counter feedback member. In this example, the stationary part 1 ’ isan integral part of the driver 43’. In this example, the driver 43’ is connected to the power source 8. Preferably, the power source 8 is a torsion spring and is configured to rotate the driver 43’ during the medicament delivery operation. In this example, the plunger rod 9’ is positioned within the body 10’ of the stationary part 1 / the driver 43’. In this example, multiple recesses / cutouts are arranged in a wall of the body 10’ and are configured to interact with the flexible arm 21a’”, 21b’” of the plunger rod 9’ when the plunger rod 9’ is axially moved relative to the driver 43’. Thus, the counter feedback member 21 a’”, 21 b’”, being at least one flexible arm, snaps over the first feedback member and the second feedback member and thereby generates two different feedback are provided.
[0064] Figs 12-13 disclose a medicament delivery device comprising the feedback assembly according to any one of examples disclosed above. The medicament delivery device comprises the housing 40 extending along the longitudinal axis L from a proximal end and a distal end. The housing 40 is configured to accommodate a medicament container containing medicament. The medicament delivery device comprises the plunger rod 9 operably connected to the power source 8 such that the plunger rod 9 is configured to be moved relative to the housing 40 by the power source 8 to expel the contained medicament. In one example, the movable part 2 is configured to be rotated relative to the housing 40 around the longitudinal axis L, as shown in Figs 9-10.
[0065] In one example, the movable part 2 is operably connected to a third feedback member 3 such that third feedback is provided when the movable part 2 is moved relative to the stationary part 1. In one example, the third feedback 3 is a different type of feedback than the first feedback and the second feedback. For example, when the first and the second feedback are audible / tactile feedback, the third is a visual indication. In this example, the third feedback member 3 comprises a rotating piece, such as a spinning wheel or a spinning ring. In one example, the housing 40 of the medicament delivery device comprises a transparent section 42. The third feedback member 3 comprises the rotating piece such that the rotating piece is configured to be rotated by the movable part 2 when the movable part 2 is moved relative to the stationary part 1. In this example, a visual indication is provided via the transparent section of the housing when the rotating piece is rotated. In a preferred example, the transparent section 42 is positioned closer to the distal end of the housing 40 than the proximal end of the housing 40.
[0066] In one example, the medicament delivery device further comprises a label 41 configured to be attached to an outer surface of the housing 40, a cap 5 configured to be attached to the proximal end of the housing 40. In one example, the cap 5 comprises a proximal part 51 and a distal part 52 having a smaller diameter than the proximal part 51. In one example, the cap comprises multiple ribs on its outer surface to facilitate gripping from an end user. In oneexample, the medicament delivery device further comprises a container carrier 6 configured to accommodate a medicament container, e.g. a syringe with an integral delivery member at its proximal end or a cartridge with a pierceable seal at its proximal end. The medicament delivery device may further comprise a locking assembly comprising a movable sleeve 7 and the driver 43; 43’. In this example, the driver is configured to rotationally lock the movable part 2 against the power source when the movable sleeve 7 is in a locking position. Thus, the movable part 2 cannot rotate when the movable sleeve 7 is in the locking position.
[0067] Furthermore, the housing 40 and / or the container carrier 6, as mentioned in any example, may be provided with (i.e ., molded in, molded with) a compound featuring persistently antimicrobial, antifungal, and / or antiviral properties. Alternatively, a compound featuring persistently antimicrobial, antifungal, and / or antiviral properties may be applied to the molded (i.e., finished) components through secondary processes (e.g., chemical vapor deposition), spraying, or dipping processes. The housing can be one single component or formed by multiple components being assembled dependent on the manufacture process. Similarly, the delivery member guard and / or the plunger rod / and / or the actuator can be one single component respectively or formed by multiple components being assembled respectively dependent on the manufacture process.
[0068] The medicament delivery devices described herein can be used for the treatment and / or prophylaxis of one or more of many different types of disorders. Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g.
[0069] Crohn’s disease and ulcerative colitis), hypercholesterolaemia, diabetes (e.g. type 2 diabetes), psoriasis, migraines, multiple sclerosis, anaemia, lupus, atopic dermatitis, asthma, nasal polyps, acute hypoglycaemia, obesity, anaphylaxis and allergies. Exemplary types of medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, antibodies, antibody-drug conjugates, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, protein analogues, protein variants, protein precursors, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies and / or protein derivatives. Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to (with non-limiting examples of relevant disorders in brackets): etanercept (rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)), evolocumab (hypercholesterolaemia), exenatide (type 2 diabetes), secukinumab (psoriasis), erenumab (migraines), alirocumab (rheumatoid arthritis), methotrexate (amethopterin) (rheumatoid arthritis), tocilizumab (rheumatoid arthritis), interferon beta-1 a (multiple sclerosis), sumatriptan (migraines), adalimumab (rheumatoid arthritis), darbepoetin alfa (anaemia), belimumab (lupus), peginterferon beta-1 a' (multiplesclerosis), sarilumab (rheumatoid arthritis), semaglutide (type 2 diabetes, obesity), dupilumab (atopic dermatitis, asthma, nasal polyps, allergies), glucagon (acute hypoglycaemia), epinephrine (anaphylaxis), insulin (diabetes), atropine and vedolizumab (inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)) , ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab, or margetuximab. Pharmaceutical formulations including, but not limited to, any drug described herein are also contemplated for use in the medicament delivery devices described herein, for example, pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier. Pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) may include one or more other active ingredients, or may be the only active ingredient present.
[0070] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, an immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
[0071] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as HER-2 receptor modulators, interleukin modulators, interferon modulators, CD38 modulators, CD22 modulators, CCR4 modulators, VEGF modulators, EGFR modulators, CD79b modulators, Trop-2 modulators, CD52 modulators, BCMA modulators, PDGFRA modulators, SLAMF7 modulators, PD-1 / PD-L1 inhibitors / modulators, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 modulators, CD3 modulators, CTLA-4 inhibitors, TIM-3 modulators, VISTA modulators, INDO inhibitors, LAG3 (CD223) antagonists, CD276 antigen modulators, CD47 antagonists, CD30 modulators, CD73 modulators, CD66 modulators, CDw137 agonists, CD158 modulators, CD27 modulators, CD58 modulators, CD80 modulators, CD33 modulators, APRIL receptor modulators, HLA antigen modulators, EGFR modulators, B-lymphocyte cell adhesion molecule modulators, CDw123 modulators, Erbb2 tyrosine kinase receptor modulators, mesothelin modulators, HAVCR2 antagonists, NY-ESO-1 0X40 receptor agonistmodulators, adenosine A2 receptors, ICOS modulators, CD40 modulators, TIL therapies, or TCR therapies.
[0072] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX, CALGB 8811 , HIDAC, MOpAD, 7 + 3, 5 +2, 7 + 4, MEC, CVP, RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA / CO, EMA / EP, EP / EMA, TP / TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini-BEAM, IGEV, C-MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VelP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE.
[0073] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those used for chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid. Exemplary chemotherapy medicaments include, byway of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
[0074] The inventive concept has mainly been described above with reference to a few examples. However, as is readily appreciated by a person skilled in the art, other embodiments than the ones disclosed above are equally possible within the scope of the inventive concept, as defined by the appended claims.
Claims
CLAIMS1. A feedback assembly of a medicament delivery device, the feedback assembly comprising:a stationary part and a movable part being movable relative to the stationary part; wherein the stationary part and the movable part are configured to be accommodated within a housing of the medicament delivery device; wherein the movable part is configured to be operably attached to a plunger rod of the medicament delivery device, or a driver of the medicament delivery device; wherein the movable part is configured to be in contact and be moved relative to the stationary part;wherein the stationary part comprises a first feedback member and a second feedback member being geometrically different from the first feedback member; and wherein the movable part comprises a counter feedback member configured to interact with the first feedback member and the second feedback member when the movable part is moved relative to the stationary part such that a first feedback is generated during the counter feedback member interacts with the first feedback member and a second feedback is generated during the counter feedback member interacts with the second feedback member thereby at least two different feedback are provided.
2. The feedback assembly according to claim 1 , wherein the magnitude of the first feedback is different from the magnitude of the second feedback.
3. The feedback assembly according to claim 1 or 2, wherein the frequency of the first feedback is different from the frequency of the second feedback.
4. The feedback assembly according to any one of the preceding claims, wherein the first feedback is an audible and / or tactile feedback; and wherein the second feedback is an audible and / or tactile feedback.
5. The feedback assembly according to any one of the preceding claims, wherein the counter feedback member is a flexible arm.
6. The feedback assembly according to any one of the preceding claims, wherein the first feedback member comprises a first protrusion; wherein the second feedback member comprises a second protrusion; and wherein the first protrusion and the second protrusion are dimensionally different from one another.
7. The feedback assembly according to any one of claims 1 -5, wherein the first feedback member comprises a first set of structural patterns; wherein the second feedback member comprises a second set of structural patterns; and wherein the structural patterns and the second structural patterns are geometrically different from one another.
8. A medicament delivery device comprises the feedback assembly according to any one of the preceding claims, wherein the medicament delivery device comprises: a housing extending along a longitudinal axis from a proximal end and a distal end; wherein the housing is configured to accommodate a medicament container containing medicament; a plunger rod operably connected to a power source such that the plunger rod is configured to be moved relative to the housing by the power source to expel the contained medicament.
9. The medicament delivery device according to claim 8, wherein the movable part of the feedback assembly is operably attached to the plunger rod.
10. The medicament delivery device according to claim 8, wherein the medicament delivery device comprises a drive connected to the plunger rod and the power source such that the plunger rod is configured to be moved relative to the housing by the power source to expel the contained medicament via the drive; and wherein the movable part of the feedback assembly is operably attached to the driver.
11. The medicament delivery device according to any one of claims 8-10, wherein the movable part is configured to be rotated relative to the housing around the longitudinal axis.
12. The medicament delivery device according to any one of claims 8-11 , wherein the movable part is operably connected to a third feedback member such that third feedback is provided when the movable part is moved relative to the stationary part.
13. The medicament delivery device according to claim 12, wherein the third feedback is a different type of feedback than the first feedback and the second feedback.
14. The medicament delivery device according to claim 12 or 13, wherein the housing of the medicament delivery device comprises a transparent section; wherein the third feedback member comprises a rotating piece such that the rotating piece is configured to be rotated by the movable part when the movable part is moved relative to the stationary part; and wherein a visual indication is provided via the transparent section of the housing when the rotating piece is rotated.1515. The medicament delivery device according to claim 14, wherein the transparent section is positioned closer to the distal end of the housing than the proximal end of the housing.
